Literature DB >> 8390490

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.

R J Whitley1, E R Kern, S Chatterjee, J Chou, B Roizman.   

Abstract

Previous studies have shown that a gene mapping in the inverted repeats of the L component of herpes simplex virus, type 1 DNA, designated as gamma (1) 34.5, was dispensable for growth in cells in culture but that the deletion mutant (R3616) and a mutant containing a stop codon (R4009) in each copy of the gene were incapable of replicating in the central nervous systems (CNS) of mice. Restoration of the deleted sequences restored the wild type virus phenotype. We report here that the gamma (1) 34.5 mutant viruses (R3616 and R4009) replicated in the vaginal tract of two different strains of mice and guinea pig, although both viruses were shed at lower titer and for fewer days than the wild type and restored viruses. Both R3616 and R4009 failed to replicate or cause significant pathology in the cornea of Balb/C mice or following intranasal inoculation of Swiss Webster mice. Analyses of sensory trigeminal and dorsal root ganglia innervating the site of inoculation indicated that the incidence of establishment of latency or reactivation from latency by R3616 and R4009 viruses was significantly lower than that determined for mice infected with wild type or restored virus. Thus, selective deletion of gamma (1) 34.5 gene abolished the capacity of the virus to spread from peripheral mucosal sites to the CNS or replicate in the CNS, and diminished the capacity of the virus to replicate at mucosal sites and, subsequently, establish latency, or be able to be reactivated ex vivo. The results of our studies may have direct implications for the development of genetically engineered herpes simplex virus vaccines.

Entities:  

Mesh:

Year:  1993        PMID: 8390490      PMCID: PMC443352          DOI: 10.1172/JCI116527

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants.

Authors:  J P Katz; E T Bodin; D M Coen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.

Authors:  J Chou; E R Kern; R J Whitley; B Roizman
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

3.  The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+.

Authors:  J Chou; B Roizman
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

4.  The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice.

Authors:  M Y Taha; S M Brown; G B Clements; D I Graham
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

5.  A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice.

Authors:  M Y Taha; G B Clements; S M Brown
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

6.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

Authors:  D M Coen; M Kosz-Vnenchak; J G Jacobson; D A Leib; C L Bogard; P A Schaffer; K L Tyler; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  The herpes simplex virus type 2 (HG52) variant JH2604 has a 1488 bp deletion which eliminates neurovirulence in mice.

Authors:  M Y Taha; G B Clements; S M Brown
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

8.  A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.

Authors:  J G Jacobson; D A Leib; D J Goldstein; C L Bogard; P A Schaffer; S K Weller; D M Coen
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

9.  Experimental therapy of human glioma by means of a genetically engineered virus mutant.

Authors:  R L Martuza; A Malick; J M Markert; K L Ruffner; D M Coen
Journal:  Science       Date:  1991-05-10       Impact factor: 47.728

10.  The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.

Authors:  J Chou; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

View more
  79 in total

1.  Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene.

Authors:  D A Leib; M A Machalek; B R Williams; R H Silverman; H W Virgin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene.

Authors:  B He; J Chou; R Brandimarti; I Mohr; Y Gluzman; B Roizman
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.

Authors:  Huali Jin; Yijie Ma; Zhipeng Yan; Bellur S Prabhakar; Bin He
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  Signals that dictate nuclear, nucleolar, and cytoplasmic shuttling of the gamma(1)34.5 protein of herpes simplex virus type 1.

Authors:  Guofeng Cheng; Marie-Elena Brett; Bin He
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment.

Authors:  Shih-Heng Chen; Angela Pearson; Donald M Coen; Shun-Hua Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Authors:  R Chambers; G Y Gillespie; L Soroceanu; S Andreansky; S Chatterjee; J Chou; B Roizman; R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Differential response of human cells to deletions and stop codons in the gamma(1)34.5 gene of herpes simplex virus.

Authors:  J Chou; A P Poon; J Johnson; B Roizman
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.

Authors:  G C Perng; R L Thompson; N M Sawtell; W E Taylor; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.